Literature DB >> 20849463

Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease.

M E A Rath1, V E H J Smits-Wintjens, I T M Lindenburg, A Brand, I L van Kamp, D Oepkes, F J Walther, E Lopriore.   

Abstract

OBJECTIVE: To evaluate neonatal outcome in Kell haemolytic disease compared to Rh D haemolytic disease. STUDY
DESIGN: Retrospective study of all (near)-term neonates with Kell (n=34) and Rh D haemolytic disease (n=157) admitted to our centre between January 2000 and December 2008. We recorded the need for exchange transfusion and top-up transfusions up to 3 months of age.
RESULTS: Neonates in the Kell group required less days of phototherapy than neonates in the Rh D group [2.4 vs. 4.1 days, respectively (P<0.01)]. The percentage of neonates requiring an exchange transfusion was lower in the Kell group than in the Rh D group [6% (2/34) and 62% (98/157), respectively (P<0.01)]. The percentage of neonates in the Kell group and Rh D group requiring a top-up transfusion was 62% (21/34) and 72% (113/157), respectively (P=0.20). The median number of top-up transfusions per neonate in the Kell group and Rh D group was 1 [interquartile range (IQR) 0-2] and 2(IQR 0-2), respectively (P=0.07).
CONCLUSION: Neonates with Kell haemolytic disease require less phototherapy and less exchange transfusions compared to neonates with Rh D haemolytic disease, but an equal number of top-up transfusions.
© 2010 The Author(s). Vox Sanguinis © 2010 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849463     DOI: 10.1111/j.1423-0410.2010.01408.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  1 in total

1.  An Easy Multiplex PCR-SSP Assay for the Genotyping of KEL1 and KEL2 in Multi-transfused Patients.

Authors:  Parinaz Zarghamian; Maryam Pourshadlou; Kamran Mousavi Hosseini; Fariba Sarem; Majid Shahabi
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-01       Impact factor: 0.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.